Our Pipeline
Sano Women’s Health is advancing a diversified pipeline of antifungal, antibacterial, and oncology therapeutics focused on diseases with significant unmet medical need. Our lead clinical program, OCF001, is in Phase 2 development for recurrent vulvovaginal candidiasis (RVVC), with additional programs targeting nipple thrush, postpartum mastitis and breast abscesses, systemic MRSA infections, and aggressive solid tumors. Powered by proprietary platform technologies, including the HOAM (Higher-Order Actin Modulating) Discovery Platform, our pipeline leverages novel mechanisms designed to address drug-resistant infections and difficult-to-treat cancers through innovative antimicrobial and actin-modulating therapeutics.
Overview
Our Pipeline
Sano Women’s Health is advancing a pipeline of novel antifungal, antibacterial, and oncology therapeutics focused on diseases with significant unmet medical need. Our programs are supported by proprietary platform technologies designed to address drug-resistant infections and difficult-to-treat cancers through innovative antimicrobial and higher-order actin modulating mechanisms.
Antifungal Therapeutics
OCF001 — Recurrent Vulvovaginal Candidiasis (RVVC) — Phase 2
OCF002 — Nipple Thrush / Breast Candidiasis — IND-Enabling
Oncology Therapeutics
OCF003 — Aggressive Solid Tumors — Preclinical
Antibacterial Therapeutics
MUT001 — Systemic MRSA — Preclinical
MUT002 — Postpartum Mastitis & Breast Abscesses — Preclinical
HOAM Discovery Platform
​​
The HOAM Discovery Platform is focused on advancing next-generation therapeutics targeting higher-order actin biology across infectious diseases and oncology.
​
Target Indications
-
Antifungal: Invasive candidiasis, aspergillosis, cryptococcosis
-
Antiparasitic: Cryptosporidium, trichomoniasis, giardiasis
-
Oncology: Breast, renal, ovarian, and other solid tumors